EchoGo Amyloidosis vs iCAC Device
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
These two FDA-cleared AI tools both operate within the Cardiology AI category, aiming for early detection of cardiovascular conditions. However, they are not direct competitors as EchoGo Amyloidosis focuses on identifying cardiac amyloidosis from echocardiograms, while the iCAC Device detects and quantifies coronary artery calcium from chest CT scans to assess cardiovascular disease risk. Therefore, they offer complementary diagnostic insights rather than overlapping functionalities.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Ultromics' EchoGou00ae Amyloidosis is designed to aid in the early detection of cardiac amyloidosis by analyzing echocardiogram video clips. Bunkerhill Health's iCAC Device detects and quantifies coronary artery calcium from routine chest CT scans to assist in early cardiovascular disease detection.
EchoGou00ae Amyloidosis analyzes echocardiogram video clips, specifically 2D echocardiograms of an apical four-chamber view. The iCAC Device analyzes routine, non-contrast, non-gated chest CT scans.
EchoGou00ae Amyloidosis provides a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis, based on echocardiographic markers like ventricular volume, cardiac function, and myocardial movement. The iCAC Device outputs a visual representation of estimated coronary artery calcium segmentation and delivers exact and four-category quantitative estimates of CAC burden in Agatston units.
EchoGou00ae Amyloidosis offers seamless integration with existing clinical workflows and IT infrastructure, including PACS, DICOM, and HL7, operating as a cloud-based SaaS model. The iCAC Device integrates with PACS or a DICOM router and supports EHR integration via the Carebricks platform, also functioning as a Software as a Medical Device (SaMD) and cloud-based solution.
EchoGou00ae Amyloidosis has a reported diagnostic accuracy of 85% sensitivity and 93% specificity for cardiac amyloidosis detection, with consistent performance across CA subtypes. The iCAC Device's performance was validated with an overall agreement of 79.7% versus ground truth and positive predictive value between 68.1% and 90.1% for calcium score groups.
EchoGou00ae Amyloidosis is primarily designed for Cardiology. The iCAC Device supports both Cardiology and Radiology specialties.